

# Validation data for THP1-Dual™ KO-DNase2 Cells


<https://www.invivogen.com/thpd-kodnase2>

For research use only

Version 22I21-AK


THP1-Dual™ KO-DNase2 cells were generated from the THP1-Dual™ cell line through the stable biallelic knockout of the *DNASE2* gene, as verified by PCR (Figure 1). Additionally, these cells feature two reporter genes allowing the simultaneous study of NF- $\kappa$ B- and IRF-induced responses by monitoring the SEAP (secreted embryonic alkaline phosphatase) and Lucia luciferase activities, respectively. There are no notable differences in the NF- $\kappa$ B- and IRF-mediated responses in THP1-Dual™ KO-DNase2 cells when compared to their parental cell line (Figures 2 and 3).

## Validation of DNASE2 knockout



**Figure 1: Validation of DNase2 KO.** The targeted DNase2 region in THP1-Dual™ (WT; blue arrow) parental cells and THP1-Dual™ KO-DNase2 (KO; red arrow) cells was amplified by PCR. THP1-Dual™ KO-DNase2 cells were generated by a biallelic deletion causing the inactivation of DNase2. The WT PCR product is ~1000 bp, whereas the truncated KO band measures only 700 bp.

## Functional validation of DNASE2 knockout (NF- $\kappa$ B response)




**Figure 2: NF- $\kappa$ B responses in THP1-Dual™-derived cells.** THP1-Dual™ and THP1-Dual™ KO-DNase2 cells were incubated with 1 ng/ml human (h)TNF- $\alpha$  (NF- $\kappa$ B-SEAP positive control), 1000 U/ml hIFN- $\beta$  (IRF-Lucia positive control), 10 ng/ml LPS-EK Ultrapure (UP; TLR4 agonist), 10  $\mu$ g/ml CLO75 (TLR7/8 agonist), 1  $\mu$ g/ml VacV70 complexed with LyoVec™ (CDS agonist), 1  $\mu$ g/ml 3p-hpRNA complexed with LyoVec™ (RIG-I agonist) and 30  $\mu$ g/ml 2'3'-cGAMP (STING agonist). After overnight incubation, the activation of NF- $\kappa$ B was assessed by measuring the activity of SEAP in the supernatant using QUANTI-Blue™ Solution. Data are shown as optical density (OD) at 630 nm (mean  $\pm$  SEM).

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Asia: +852 3622-3480  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)

### Functional validation of DNASE2 knockout (IRF response)



**Figure 3: IRF responses in THP1-Dual™-derived cells.** THP1-Dual™ and THP1-Dual™ KO-DNase2 cells were incubated with 1 ng/ml human (h)TNF- $\alpha$  (NF- $\kappa$ B-SEAP positive control), 100 ng/ml LPS-EK Ultrapure (TLR4 agonist), 10  $\mu$ g/ml CLO75, 10  $\mu$ g/ml R848 (both TLR7/8 agonists), 1  $\mu$ g/ml VacV70 complexed with LyoVec™ (CDS agonist), 1  $\mu$ g/ml 3p-hpRNA complexed with LyoVec™ (RIG-I agonist) and 30  $\mu$ g/ml 2'3'-cGAMP (STING agonist). After overnight incubation, the IRF response was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. The IRF induction of each ligand is expressed relative to that of hIFN- $\beta$  at  $1 \times 10^3$  U/ml (mean  $\pm$  SEM).

#### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: [info@invivogen.com](mailto:info@invivogen.com)